There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opthea Limited (CKDXF – Research Report) and Glaukos (GKOS – Research Report) with bullish sentiments.
Opthea Limited (CKDXF)
In a report issued on July 25, Melissa Benson from Wilsons maintained a Buy rating on Opthea Limited, with a price target of A$1.50. The company’s shares closed last Thursday at $0.42, close to its 52-week low of $0.41.
According to TipRanks.com, Benson is a 2-star analyst with an average return of
Currently, the analyst consensus on Opthea Limited is a Moderate Buy with an average price target of $1.01.
See Insiders’ Hot Stocks on TipRanks >>
Glaukos (GKOS)
In a report released yesterday, Thomas Stephan from Stifel Nicolaus maintained a Buy rating on Glaukos, with a price target of $90.00. The company’s shares closed last Wednesday at $75.96, close to its 52-week high of $80.28.
Stephan has an average return of
According to TipRanks.com, Stephan is ranked #4455 out of 8533 analysts.
Currently, the analyst consensus on Glaukos is a Moderate Buy with an average price target of $78.11, implying a 4.7% upside from current levels. In a report issued on July 17, BTIG also maintained a Buy rating on the stock with a $83.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CKDXF:
- Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
- Oppenheimer biotechnology analysts to hold an analyst/industry conference call
- Opthea to Present at the 2023 Ophthalmology Innovation Summit
- Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting
- Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
